Credit Suisse Services AG Pleads Guilty to US Tax Evasion, Will Pay $510 Million
Credit Suisse Services AG pleaded guilty to conspiring with U.S. taxpayers to conceal more than $4 billion in offshore accounts, agreeing to pay more than $510 million in penalties, the U.S. Department of Justice (DOJ) announced on May 5.
The Swiss corporation also admitted to violating a previous 2014 plea agreement and entered into a separate non-prosecution agreement over related conduct in Singapore.
The plea stems from a multiyear investigation into Credit Suisse's role in assisting ultra-high-net-worth and high-net-worth U.S. clients in hiding assets from the IRS, the DOJ announcement stated.
According to court documents, between 2010 and July 2021, Credit Suisse AG and its employees worked with U.S. customers and others to maintain undeclared offshore accounts, falsify records, and process fictitious documents—actions that the DOJ said enabled continued tax evasion and noncompliance with federal reporting laws.
'Among other fraudulent acts, bankers at Credit Suisse falsified records, processed fictitious donation paperwork, and serviced more than $1 billion in accounts without documentation of tax compliance,' the DOJ noted in the announcement.
The actions not only allowed clients to avoid filing required Foreign Bank and Financial Accounts (FBAR) reports but also breached the terms of Credit Suisse's May 2014 plea deal with the United States. That prior agreement required the bank to avoid further criminal conduct.
Related Stories
11/28/2024
8/14/2023
In addition to the plea, Credit Suisse Services AG signed a non-prosecution agreement with the DOJ's Tax Division and the U.S. Attorney's Office for the Eastern District of Virginia regarding legacy accounts at Credit Suisse AG Singapore.
That office maintained accounts with more than $2 billion in assets for U.S. persons between 2014 and June 2023, failing to properly identify account holders or investigate U.S. ties.
UBS, which acquired Credit Suisse in 2023, discovered potentially undeclared accounts during the post-merger integration and voluntarily disclosed the findings to U.S. authorities. Some accounts were frozen, and UBS launched an internal investigation.
In a statement after the agreement was reached this week, UBS said that it 'was not involved in the underlying conduct and has zero tolerance for tax evasion.'
'With this resolution, UBS is pleased to have resolved another of Credit Suisse's legacy issues, in line with UBS's intention to resolve legacy matters at pace in a fair and balanced way and in the best interest of all its stakeholders,' UBS added in its statement.
Under the terms of the agreements, Credit Suisse Services AG must cooperate fully with ongoing investigations and disclose any future discoveries related to U.S.-linked accounts.
In total, Credit Suisse Services AG will pay $510,608,909 in penalties, restitution, forfeiture, and fines.
Of that, $371.9 million is tied to the guilty plea, while $138.7 million stems from the non-prosecution agreement related to conduct in Singapore.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
UBS Capital Requirements Rise Following Switzerland's Proposal
Switzerland's Federal Department of Finance ('FDF') has proposed stricter rules for UBS Group AG UBS following its takeover of Credit Suisse. The move has been attempted to reduce the risks of another Credit Suisse-style Swiss government has proposed that UBS should fully capitalize its foreign subsidiaries, up from the current 60% threshold. This will require UBS to increase its common equity tier-one capital by up to $26 bank will be allowed to reduce its Additional Tier 1 (AT1) bond holdings by $8 billion. Still, this will result in a net increase of $18 billion in FDF stated, 'The Credit Suisse crisis made it clear that the Swiss parent bank's capital base was insufficient. The implementation of the package of measures is intended to substantially reduce the likelihood that another systemically important bank in Switzerland will get into a severe crisis, and that emergency measures by the state will be required.'Per the FDF, this estimate assumed no change in UBS's balance sheet size, risk-weighted assets or its potential use of mitigation said it 'strongly disagrees with the extreme increase in capital requirements that has been proposed. These changes would result in capital requirements that are neither proportionate nor internationally aligned.'Notably, the 'too big to fail' proposals (still subject to parliamentary approval) have come after the Swiss financial regulator granted capital relief to Credit Suisse in 2017, allowing the bank to inflate the value of its foreign the new capital proposals will be put out for consultation before being submitted to the the FDF, the proposed reforms will not become law before 2028, and UBS will be given a six to eight-year transition period to implement the changes once the legislation comes into force. UBS took over its rival Credit Suisse in a state-sponsored rescue in then, UBS has been facing challenges and legal claims, which is increasing costs. Last month, UBS agreed to pay $511 million to resolve a tax probe by the U.S. Department of Justice against Credit Suisse for preparing false income tax returns and tax UBS is on track to substantially complete the integration of Credit Suisse by the end of 2026 and, hence, achieve the targeted cost the first quarter of 2025, UBS completed consolidating its branch network in Switzerland, merging 95 branches since the July 2024 merger with Credit Suisse. The company is initiating its Swiss business migrations and aims to complete the migrations by the first quarter of the first quarter of 2025, UBS realized an additional $0.9 billion in gross cost savings. Cumulative gross cost savings at the end of the first quarter of 2025 amounted to $8.4 billion compared with the 2022 combined cost base of UBS and Credit Suisse. This represents around 65% of its ambition to deliver $13 billion in annualized exit rate gross cost savings by the end of 2026. Over the past six months, UBS shares have gained 6.1% compared with the industry's growth of 23.1%. Image Source: Zacks Investment Research Currently, UBS carries a Zacks Rank #3 (Hold). A couple of better-ranked peer stocks are Deutsche Bank Aktiengesellschaft DB and Mitsubishi UFJ Financial Group, Inc. MUFG, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks estimates for DB for the current year have been revised 4.2% upward over the past 60 days. Over the past six months, DB shares have soared 57.7%.MUFG's current fiscal-year earnings estimates have been revised 4.6% higher over the past 60 days. MUFG shares have gained 16.5% over the past six months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Deutsche Bank Aktiengesellschaft (DB) : Free Stock Analysis Report UBS Group AG (UBS) : Free Stock Analysis Report Mitsubishi UFJ Financial Group, Inc. (MUFG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Milwaukee County Judge Dugan case, prosecutors urge court not to dismiss
The Brief The Trump administration is opposing the dismissal of charges against Milwaukee County Circuit Court Judge Hannah Dugan. Dugan is accused of helping a man evade immigration agents in her courthouse. DOJ attorneys argue dropping the charges would set a dangerous precedent, implying judges are above the law. MILWAUKEE - A federal motion has been filed in response to Milwaukee County Circuit Court Judge Hannah Dugan's request to dismiss the case against her. And after reading through the 25-page motion, federal prosecutors say Dugan is not above the law. The indictment against Dugan alleges she helped an undocumented man who was wanted on a federal warrant avoid arrest by I.C.E. agents. SIGN UP TODAY: Get daily headlines, breaking news emails from FOX6 News Click to open this PDF in a new window. In Dugan's motion for dismissal, she asked the court to dismiss the indictment based on judicial immunity. But today (June 9), federal prosecutors came back saying her request was unprecedented and quote "would, in essence, say that judges are above the law." Dugan faces a July 21 trial in the case that escalated a clash between Trump's administration and opponents over the Republican president's sweeping immigration crackdown. Trump critics contend that Dugan's arrest went too far and that the administration is trying to make an example out of her to discourage judicial opposition to the crackdown. The backstory Dugan is charged with concealing an individual to prevent arrest, a misdemeanor, and obstruction, which is a felony. Prosecutors say she escorted Eduardo Flores-Ruiz, 31, and his lawyer out of her courtroom through a back door on April 18 after learning that U.S. Immigration and Customs Enforcement agents were in the courthouse seeking to arrest him for being in the country illegally. She could face up to six years in prison and a $350,000 fine if convicted on both counts. Her attorneys say she's innocent. They filed a motion last month to dismiss the case, saying she was acting in her official capacity as a judge and therefore is immune to prosecution. They also maintain that the federal government violated Wisconsin's sovereignty by disrupting a state courtroom and prosecuting a state judge. The other side Justice Department attorneys responded in a court filing Monday, saying dismissing the charges against the judge on the grounds that she is immune would be unprecedented and would ignore "well-established law that has long permitted judges to be prosecuted for crimes they commit." "Such a ruling would give state court judges carte blanche to interfere with valid law enforcement actions by federal agents in public hallways of a courthouse, and perhaps even beyond," Justice Department attorneys argued. "Dugan's desired ruling would, in essence, say that judges are 'above the law,' and uniquely entitled to interfere with federal law enforcement." Dugan's attorney, Craig Mastantuono, did not immediately respond to messages seeking comment. In her motion to dismiss, Dugan argued that her conduct amounted to directing people's movement in and around her courtroom, and that she enjoys legal immunity for official acts she performs as a judge. She also accused the federal government of violating Wisconsin's sovereignty by disrupting a state courtroom and prosecuting a state judge. Dugan's case is similar to one brought during the first Trump administration against a Massachusetts judge, who was accused of helping a man sneak out a courthouse back door to evade a waiting immigration enforcement agent. That case was eventually dismissed. The backstory According to prosecutors, Eduardo Flores-Ruiz illegally reentered the U.S. after being deported in 2013. He was charged in March with misdemeanor domestic violence in Milwaukee County and was in Dugan's courtroom for a hearing in that case on April 18. Dugan's clerk alerted her that immigration agents were in the courthouse looking to arrest Flores-Ruiz, prosecutors allege in court documents. According to an affidavit, Dugan became visibly angry at the agents' arrival and called the situation "absurd." After discussing the warrant for Flores-Ruiz's arrest with the agents, Dugan demanded that they speak with the chief judge and led them away from the courtroom. She then returned to the courtroom, was heard saying something to the effect of "wait, come with me," and then showed Flores-Ruiz and his attorney out a back door, the affidavit says. The immigration agents eventually detained Flores-Ruiz outside the building following a foot chase. Dugan, 66, was arrested by the FBI on April 25 at the courthouse. A grand jury indicted Dugan on May 13 and she pleaded not guilty on May 15. FREE DOWNLOAD: Get breaking news alerts in the FOX LOCAL Mobile app for iOS or Android What we know A legal defense fund created by Dugan supporters to help pay for her high-profile defense attorneys has raised more than $137,000 in three weeks from more than 2,800 donors. Her legal team includes former U.S. Attorney Steve Biskupic and former U.S. Solicitor General Paul Clement. Both were appointed by Republican presidents. She has also hired prominent attorneys in Milwaukee and Madison. "This is an impressive show of support for the defense fund, highlighting that the public believes in protecting a fair and independent judiciary," former Supreme Court Justice Janine Geske, the fund's trustee, said Monday. "The fund will continue to raise grassroots donations and uphold strict guidelines to ensure transparency and accountability." Dugan is not required to list the donor names until she submits her annual financial disclosure form, which is due in April. Numerous people are prohibited from donating, including Milwaukee County residents; attorneys who practice in the county; lobbyists; judges; parties with pending matters before any Milwaukee County judge; and county employees. The Source FOX6 has done significant reporting on the arrest and charges filed against Milwaukee County Judge Hannah Dugan. FOX6 produced this story with information from the federal motion, with contributions from the Associated Press.
